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In response to DNA damage, mammalian
cells trigger the p53-dependent transcrip-
tional induction of factors that regulate
DNA repair, cell-cycle progression, or cell
survival. Through differential proteomics,
we identify heterogeneous nuclear ribonu-
cleoprotein K (hnRNP K) as being rapidly in-
duced by DNA damage in a manner that re-
quires the DNA-damage signaling kinases
ATM or ATR. Induction of hnRNP K en-
sues through the inhibition of its ubiquitin-
dependent proteasomal degradation me-
diated by the ubiquitin E3 ligase HDM2/
MDM2. Strikingly, hnRNP K depletion abro-
gates transcriptional induction of p53 target
genes and causes defects in DNA-damage-
induced cell-cycle-checkpoint arrests. Fur-
thermore, in response to DNA damage, p53
and hnRNP K are recruited to the promoters
of p53-responsive genes in a mutually de-
pendent manner. These findings establish
hnRNP K as a new HDM2 target and show
that, by serving as a cofactor for p53,
hnRNP K plays key roles in coordinating
transcriptional responses to DNA damage.
INTRODUCTION
The eukaryotic DNA-damage response (DDR) has evolved to
optimize cell survival following damage to the genome. Key
DDR regulators are the phosphatidylinositol 3-kinase-like
kinases (PIKKs) ataxia telangiectasia mutated (ATM), ATM
and Rad3 related (ATR), and DNA-dependent protein kinaseCellcatalytic subunit (DNA-PKcs), which are activated following
DNA damage and then phosphorylate downstream targets
(Abraham, 2004; Shiloh et al., 2004). Targets of ATM and
ATR include transcription factor p53 and the checkpoint
kinases CHK1 and CHK2; these in turn regulate the activities
of downstream effector proteins controlling DNA repair, cell-
cycle progression, or the initiation of apoptotic or senes-
cence programs.
In addition to being an important target of ATM and ATR,
p53 is the most frequently mutated protein known in human
cancers, with loss of p53 function thought to contribute to
tumorigenesis by fostering genome instability and the con-
sequent acquisition of additional oncogenic mutations
(Vousden and Prives, 2005). A fundamental property of
p53 is that its levels and transcriptional activity are markedly
induced by DNA damage and a range of other cellular
stresses. Under normal conditions, p53 activity is maintained
at low, basal levels through the actions of HDM2 (originally
identified in mice as the murine double minute 2 protein,
MDM2). HDM2 acts as a ubiquitin E3 ligase to transfer ubiq-
uitin moieties onto p53, thus promoting p53 degradation via
the ubiquitin-dependent proteasomal system (Haupt et al.,
1997; Kubbutat et al., 1997). In response to DNA damage,
negative regulation of p53 by HDM2 is lifted, leading to sta-
bilization of transcriptionally competent p53. This control is
brought about in part by ATM- and ATR-mediated phos-
phorylation of both p53 and HDM2, which impairs the inter-
action between the two proteins (Perry, 2004).
A major consequence of p53 activation following DNA
damage is the induction of cell-cycle arrest at the G1/S or
G2/M transition stages. This is achieved primarily through
p53-induced expression of target genes that encode factors
such as p21WAF/CIP, a negative regulator of cyclin-dependent
kinases (CDKs) that induces G1/S arrest (Bartek and Lukas,
2001), and proteins such as GADD45, 14-3-3s, and Rep-
rimo that are needed for an efficient G2/M arrest following
DNA damage (Taylor and Stark, 2001). The importance of
these transcriptional responses is highlighted by the fact
that over 90% of known tumor-derived p53 mutations occur
in its DNA binding domain (Hainaut and Hollstein, 2000). The123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc. 1065
Figure 1. Induction of hnRNP K by IR Is ATM Dependent
(A) In 2D DIGE, spectrally distinct fluorescent Cy dyes are used to label proteins of different cell lysates before mixing and running these on the same 2D gel.
Differences in levels of individual protein spots between lysates are determined after fluorescent imaging and analysis.
(B) Profile of a nuclear protein upregulated in response to IR in an ATM-dependent manner and later identified bymass spectrometry as hnRNPK. Left panel:
relative abundance of this highlighted hnRNP K spot in lysates from GM14680 cells (wild-type ATM) obtained 3 hr after 20 Gy of IR exposure in either the1066 Cell 123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc.
pivotal role of p53 in cellular stress responses is reflected by
the complex regulatory mechanisms that control its activity;
these include the existence of many forms of p53 posttrans-
lational modification, the regulation of p53 DNA binding ac-
tivity by other transcription factors, and the cooperation of
p53 with transcriptional coactivators that modify chromatin
structure and/or facilitate transcription-complex formation
(Coutts and La Thangue, 2005).
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is
an evolutionarily conserved factor found in the nucleus and
cytoplasm that was initially discovered as a component of
hnRNP complexes (Matunis et al., 1992). Since then, work
has implicated hnRNP K in processes including chromatin
remodeling and transcription as well as mRNA splicing, ex-
port, and translation (Bomsztyk et al., 2004). The involve-
ment of hnRNP K in these events appears to reflect its ability
to interact with a range of molecular partners, including DNA,
RNA, protein kinases, and proteins involved in chromatin re-
modeling (Bomsztyk et al., 1997, 2004). Perhaps the most
characterized function of hnRNP K is its role in transcription.
For example, it has been reported to associate with the kB
enhancer motif (Ostrowski et al., 1994); to enhance the ex-
pression of the c-myc, EGR, and BRCA1 genes (Michelotti
et al., 1996; Ostrowski et al., 2003; Thakur et al., 2003);
to activate or repress RNA polymerase II transcription in a
context-dependent manner (Lee et al., 1996; Michelotti
et al., 1996; Tomonaga and Levens, 1995, 1996); and to
stimulate transcription by purified RNA polymerase II in vitro
(Gaillard et al., 1994). Although the available data suggest
that these effects reflect the ability of hnRNP K to bind with
high affinity to single-stranded DNA (ssDNA; Tomonaga
and Levens, 1995, 1996), the precise mechanisms by which
hnRNP K regulates transcription and the ways in which
hnRNP K is itself regulated remain largely obscure.
Here, by studying PIKK-dependent proteomic changes
that occur in human cells in response to DNA damage, we
identify hnRNP K as a protein that is upregulated in response
to DNA damage in an ATM- and ATR-dependent manner.
Furthermore, we show that hnRNP K is stabilized following
DNA damage through the inhibition of its HDM2-mediated
ubiquitin-dependent degradation. Finally, by investigating
the functional consequences of hnRNP K depletion from
cells, we establish that it is crucial for DNA-damage-induced
cell-cycle-checkpoint arrest and serves as a transcriptional
cofactor for p53.CellRESULTS
Proteomic Analysis Identifies hnRNP K as a Candidate
for ATM-Dependent Regulation
To analyze the DDR, we used the differential proteomic tech-
nology of two-dimensional difference gel electrophoresis (2D
DIGE; Unlu et al., 1997). 2D DIGE overcomes a major hurdle
encountered with traditional 2D gel methods—the difficulty
in matching protein spots from multiple samples run on dif-
ferent gels—by labeling proteins from different samples with
spectrally distinct fluorescent cyanine (Cy) dyes, mixing the
samples, and then running them on the same gel before over-
laying the separate fluorescent images (Figure 1A; Gharbi
et al., 2002). In a 2DDIGE analysis of changes in nuclear pro-
teins in response to ionizing radiation (IR), we used as con-
trols both a potent and specific small molecule inhibitor of
the ATM kinase (KU-55933; Hickson et al., 2004) and A-T
cells that fail to express functional ATM protein. Figure 1B
illustrates the profile of a protein species that was identified
by mass spectrometry as hnRNP K. In GM14680 lympho-
blastoid cells that contain functional ATM, this protein spe-
cies was induced following IR treatment; however, in the
same cells exposed to the ATM inhibitor KU-55933, or in
ATM-deficient GM01526 cells, the amount of the protein
following IR treatment was 3- to 4-fold lower, suggesting
that hnRNP K is regulated by ATM kinase activity.
To confirm and further characterize hnRNP K induction in
response to DNA damage, we carried out immunoblot anal-
yses with a monoclonal antibody directed against it (Matunis
et al., 1992). This revealed that hnRNP K levels increased 2-
to 3-fold within 15 min after exposure of MRC5 fibroblast
cells to IR or following their acute treatment with the radiomi-
metic drug phleomycin (Figure 1C). In each case, hnRNP K
returned to near basal levels within 3 hr of treatment. The ini-
tial identification of hnRNP K by 2D DIGE analysis at the 3 hr
time point presumably reflects the high sensitivity of this
method. This transient increase in hnRNP K was also ob-
served by indirect immunofluorescence analysis of irradiated
cells (data not shown). Importantly, in contrast to control
cells where hnRNP K induction was transient, hnRNP K in-
duction was still observed 12 hr after IR treatment of
180BR cells that bear a mutation in the gene for DNA ligase
IV (Figure 1D). Since 180BR cells are specifically defective in
repairing DNA double-strand breaks (DSBs; Riballo et al.,
1999), these data reveal that it is DSBs and not otherpresence or absence of KU-55933. Right panel: abundance of the hnRNP K spot relative to the mean level observed in untreated GM14680 cells (blue
circles), in the same cells treated with IR (red circles) or with IR and KU-55933 (yellow circles), or in IR-treated GM01526 cells that lack functional ATM (green
circles). All lysates treated with IR were obtained 3 hr postirradiation.
(C) MRC5 cells were untreated (unt) or treated with 20 Gy of IR or 100 mg/ml of phleomycin (Phleo) and incubated for the times indicated. Immunoblot anal-
ysis was with an hnRNP K monoclonal antibody (K) or an anti-tubulin antibody (Tub).
(D) hnRNP K was assessed up to 12 hr following IR (10 Gy) in wild-type fibroblasts (control) or DSB-repair-defective 180BR cells.
(E) hnRNP K in extracts of normal fibroblast cells (MRC5) or ATM-defective AT fibroblasts stably transfected with either empty vector (empVec) or an ATM-
expressing construct (+ATM). Cells were untreated (unt) or treated with 15 Gy IR or 100 mg/ml of phleomycin (Ph) 1 hr before harvesting and assessing
hnRNP K levels (K). An anti-tubulin antibody (Tub) was used as a control, and a CHK2 phosphospecific antibody (Chk2pT68) was used to confirm ATM
activity.
(F) hnRNP K was assessed following IR (15 Gy) at the times indicated in either the presence or absence of 10 mMKU-55933, as indicated. Given below (C)–
(F) is the fold of increase (FI) in hnRNP K following DNA damage relative to the relevant untreated sample.123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc. 1067
IR-induced lesions that trigger increased hnRNP K levels.
Furthermore, while treatment with IR or phleomycin led to
hnRNP K induction in ATM-positive MRC5 cells and in A-T
cells complemented with the wild-type ATM gene, this was
not the case for ATM-defective cells (Figure 1E). Moreover,
hnRNP K induction following IR or phleomycin treatment re-
quired ATM kinase activity as it was prevented by the ATM
inhibitor KU-55933 (Figure 1F). Taken together, these data
reveal that hnRNP K levels are rapidly induced by DSBs in
a manner that requires the kinase activity of ATM.
hnRNP K Is Induced by UV in a ATR-Dependent
Manner
To determine whether hnRNP K induction is specific to DNA
damage or is amore general response to stress, we exposed
cells to ultraviolet (UV) light, hypotonic conditions, hypertonic
conditions, or heat shock. Of these treatments, only UV
resulted in an appreciable and reproducible induction of
hnRNP K levels, suggesting that hnRNP K is specifically in-
duced by DNA damage (Figure 2A). Indeed, while UV-medi-
ated elevation of hnRNP K was transient in repair-proficient
MRC5 fibroblasts, its induction was much more protracted
in xeroderma pigmentosum group A (XPA) cells (Ichikawa
et al., 2000) that are defective in nucleotide-excision repair
of UV-induced DNA lesions (Figure 2B). In contrast to induc-
tion of hnRNP K by IR, its UV-mediated induction still took
place in A-T cells (data not shown) and in cells treated with
the ATM inhibitor KU-55933 (Figure 2C). However, UV-medi-
ated induction of hnRNP K was prevented by wortmannin or
caffeine, which inhibit both ATM and ATR (Sarkaria et al.,
1998), suggesting that it might rely on ATR. Indeed, while
hnRNP K was induced by UV in cells treated with a control
siRNA (si-GFP), induction did not take place in cells that
had been siRNA depleted of ATR (si-ATR; Figure 2D).
Thus, hnRNP K induction following UV exposure is ATR
dependent.
hnRNP K Induction after DNA Damage Reflects
Inhibition of Its Ubiquitin-Mediated Degradation
While characterizing hnRNP K levels in cells exposed to cy-
cloheximide, a potent inhibitor of mRNA translation, we
found that both IR and UV led to a marked increase in
hnRNP K half-life in comparison to unirradiated controls (Fig-
ure 3A and data not shown). Thus, hnRNP K induction must
occur at least in part through its posttranslational stabiliza-
tion, possibly through inhibition of its degradation. As the
major pathway for regulated protein degradation in eukary-
otic cells is the ubiquitin-dependent proteasomal pathway,
we used the proteasome inhibitor MG132. As shown in Fig-
ure 3B, when cells were not treated with a DNA-damaging
agent, MG132 led to significantly higher hnRNP K levels.
Moreover, in the presence of MG132, levels of hnRNP K
were not further increased upon IR or UV treatment (Fig-
ure 3B and data not shown). These data suggest that, as
for p53, hnRNP K levels are controlled by proteasome-
mediated degradation and that, following DNA damage, this
process is disrupted, leading to hnRNP K induction.
To test the above model, we incubated U2OS cells in the
presence or absence of MG132, mock treated or treated the1068 Cell 123, 1065–1078, December 16, 2005 ª2005 Elseviercells with IR, and prepared protein extracts from them. We
then immunoprecipitated hnRNP K and analyzed the immu-
noprecipitates by immunoblotting with an antibody directed
against hnRNP K. Notably, when cells had been treated with
MG132, in addition to there being a band corresponding to
unmodified hnRNP K, we also detected a series of additional,
more slowly migrating forms of the protein (Figure 3C).
Figure 2. Induction of hnRNP K in Response to UV Is ATR
Dependent
(A) MRC5 fibroblasts were exposed to different stress factors, including
UV, and, 1 hr after exposure, hnRNP K (K) was evaluated by Western im-
munoblot analysis with anti-hnRNP K antibody. Tubulin (Tub) was as-
sessed as a loading control.
(B) Effect of UV (25 J/m2) treatment on hnRNP K in normal fibroblasts or
XPA cells.
(C) hnRNP K levels in MRC5 cells 1 hr after UV (25 J/m2) exposure in
the presence of wortmannin (10 mM; +Wort), caffeine (5 mM; +Caf), or
KU-55933 (10 mM).
(D) Levels of hnRNP K (K), ATR, and tubulin (Tub) were evaluated in ex-
tracts from U2OS cells treated with control siRNA (si-GFP) or ATR siRNA
(si-ATR) with or without subsequent UV exposure.Inc.
Figure 3. hnRNP K Stabilization following DNA Damage Reflects Inhibition of Its Proteasomal Degradation
(A) U2OS cells were pretreated with cycloheximide (CHX), mock () treated or treated with IR (20Gy), and incubated in the presence of cycloheximide for the
times indicated before determining hnRNP K (K) or tubulin (Tub) levels by Western blotting (WB).
(B) U2OS cells were treated with MG132 (30 mM) for 3 hr prior to IR (20 Gy), and, after incubation for the times indicated, hnRNP K levels (K) were evaluated
by WB.
(C) Extracts from U2OS cells, either with or without MG132 or IR (20 Gy) treatment, were analyzed by immunoprecipitation (IP) with an anti-hnRNP K an-
tibody followed by WB with the same antibody. Bands representing hnRNP K (K) and the immunoglobulin light chain (Ig) are indicated. The input lane con-
tains 5% of the material used in the IP, and an unrelated antibody (UIg) was used as a specificity control.
(D) Immunoprecipitates from experiments in (C) were subjected to WB analysis with an anti-ubiquitin antibody.These additional bands were not observed in extracts from
cells that had not been MG132 treated, suggesting that
they might correspond to hnRNP K ubiquitin conjugates
(Figure 3C). Indeed, the more slowly migrating forms of
hnRNP K were recognized in parallel immunoblots probed
with an antibody directed against ubiquitin (Figure 3D). Most
strikingly, while the ubiquitin-modified forms of hnRNP K
were observed in unirradiated cells, they were virtually un-
detectable 1 hr after IR treatment but reappeared 3 hr post-
irradiation (Figures 3C and 3D). These results imply that
stabilization of hnRNP K following DNA damage reflects a
transient inhibition of its ubiquitin-dependent proteasomal
degradation.
HDM2 Is a Negative Regulator of hnRNP
K Protein Levels
Protein ubiquitylation results from a tightly regulated enzy-
matic cascade, and, in many cases, the last step of the
cascade—the transfer of the ubiquitin moiety onto a specific
target—is mediated by an E3 ubiquitin ligase protein (Pickart
and Eddins, 2004). An E3 ligase that has been strongly linked
to the DDR is human HDM2 (the ortholog of mouse MDM2).
HDM2/MDM2 negatively regulates p53 in undamaged cells
by directly binding p53 and blocking its transcriptional activ-
ity and also by stimulating p53 nuclear export and proteaso-
mal degradation (Iwakuma and Lozano, 2003). This negative
regulation is transiently alleviated following DNA damage,Celland, in the case of IR, it is ATM dependent. Given the similar
profiles and PIKK requirements of hnRNP K and p53 induc-
tion following IR, we speculated that HDM2 might also inter-
act with and regulate hnRNPK. Indeed, HDM2was coimmu-
noprecipitated with hnRNP K from extracts derived from
unirradiated cells. Moreover, this coimmunoprecipitation
rapidly diminished following the irradiation of cells but was
reestablished 3 hr postirradiation (Figures 4A and 4B). To fur-
ther analyze the interaction between hnRNP K and HDM2,
we used Nutlin, a recently discovered antagonist of the
HDM2-p53 interaction (Vassilev et al., 2004). While Nutlin
enhanced p53 levels equivalent to those generated by IR,
it did not cause detectable changes in hnRNP K levels (see
Figure S1A in the Supplemental Data available with this arti-
cle online). These data imply that the HDM2-hnRNP K inter-
action does not require p53 and suggest that the molecular
nature of the p53-HDM2 interaction is likely to be distinct
from that of the HDM2-hnRNP K interaction.
The above results suggested that HDM2might destabilize
hnRNP K and that this destabilizing activity is abrogated in
response to DNA damage. In line with this model, we found
that siRNA-mediated downregulation of HDM2 in SAOS2
cells led to induction of hnRNP K protein levels (Figure 4C).
Furthermore, when we analyzed a panel of cancer cell lines
displaying markedly different levels of HDM2—previously
attributed to the presence or absence of functional p53
(Ramos et al., 2001)—there was an inverse correlation123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc. 1069
Figure 4. HDM2 Mediates Ubiquitin-Dependent Degradation of hnRNP K
(A) Lysates fromU2OScells,mock treated or treatedwith IR (20Gy) and incubated for the times indicated,were subjected to IPwith hnRNPKantibody (IP/a-K)
andanalyzedbyWesternblotting (WB)with anHDM2 (a-HDM2) or an hnRNPK (a-K) antibody.Anunrelated antibodywasusedas a specificity control (IP/UIg).
(B) U2OS cells were transfected with an HA-tagged HDM2 expression vector and subjected to IP with HA antibody (IP/a-HA) after being mock treated or IR
treated and incubated for the indicated times. Immunoprecipitates were analyzed by WB with hnRNP K (a-K) antibody or HA antibody (a-HA).
(C) SAOS2 cells were treated with control siRNA (si-GFP) or HDM2 siRNA (si-HDM2), and, 48 hr after treatment, extracts were subjected to WB with anti-
HDM2 (HDM2) or hnRNP K (K) antibodies. Actin (act) antibody was used as a control.
(D)Mdm2-defective MEFs were transfected with empty vector (+Vec) or an HA-MDM2 vector expressing either full-length MDM2 (+HA-MDM2FL) or RING-
finger-deleted MDM2 (+HA-MDM2Dring). Cells were then mock treated or treated with IR (20 Gy) and incubated for the indicated times. Cells transfected
with the full-length MDM2 expression vector were also either mock treated or treated with MG132. Lysates were then prepared and subjected to WB with
hnRNP K antibody (K), HA antibody (HA) for detection of HA-MDM2, or actin antibody.
(E) Mdm2-defective MEFs complemented as described in (D) were mock treated or treated with IR (20 Gy) and incubated for the indicated times before
subjecting to IP with hnRNP K antibody followed by WB with hnRNP K antibody (a-K) or ubiquitin antibody (a-Ub). Ubiquitin-modified forms of hnRNP K
(Ub-K) and hnRNP K (K) are indicated. The asterisk indicates a nonspecific band.
(F) HDM2-mediated in vitro ubiquitylation of hnRNP K (see Experimental Procedures).between the levels of HDM2 and those of hnRNP K (Figure
S1B). Indeed, induction of hnRNP K in response to DNA
damage was not generally seen in cells displaying low1070 Cell 123, 1065–1078, December 16, 2005 ª2005 Elsevier InHDM2 levels, probably attributable to mutations in p53
(data not shown). To more rigorously address the functional
relationship between hnRNP K and HDM2, we used mousec.
embryonic fibroblasts (MEFs) deleted for both copies of the
Mdm2 and p53 genes (Mdm2/ p53/; Montes de Oca
Luna et al., 1995). In Mdm2/ p53/ cells transfected
with parental vector, hnRNP K levels were not induced by
IR, and the profile of hnRNP K expression corresponded to
that of MDM2-competent cells in the presence of MG132,
with constitutively high levels of the protein (Figure 4D; see
also Figure 3B). Significantly, the introduction of MDM2
into Mdm2/ p53/ cells led to a marked reduction of
hnRNP K levels in unirradiated cells and restored the ability
of IR to induce hnRNP K in a manner that was abolished
by the MG132 (Figure 4D). Furthermore, these effects were
mediated by wild-type MDM2 but not by a RING-finger-
deleted version (MDM2Dring) of the protein that is deficient
in E3 ligase activity (Figure 4D). Consistent with these find-
ings, while incubation with MG132 allowed detection of
ubiquitin-modified forms of hnRNP K in MDM2-negative
cells transfected with wild-type Mdm2 (Figure 4E), these
ubiquitylated forms were not apparent in MG132-treated
cells transfected with either the RING-deleted derivative of
Mdm2 or an empty vector (Figure 4E). To see whether
HDM2 could serve as a direct E3 ligase for hnRNP K, we per-
formed in vitro ubiquitylation assays with purified proteins. In-
deed, while no ubiquitylation was observed in the presence
of the HDM2Dring protein, hnRNP K ubiquitylation was
clearly mediated by wild-type HDM2. Together, these results
reveal that MDM2/HDM2 serves as a DNA-damage-regu-
lated ubiquitin E3 ligase for hnRNP K.
hnRNP K Is Required for p53-Mediated
Cell-Cycle-Checkpoint Responses
To probe hnRNP K function, we developed siRNA duplexes
that rapidly and efficiently downregulated it in a range of cell
lines (Figures 5A and 5B and data not shown). Importantly,
downregulation of hnRNP K for up to 48 hr did not cause sig-
nificant levels of cell death, thus allowing us to explore the ef-
fects of hnRNP K depletion on cell-cycle progression in the
presence or absence of DNA damage. To address the pos-
sible role of hnRNPK in regulating cell-cycle checkpoints, we
treated telomerized MRC5 fibroblast cells with control or
hnRNP K siRNA oligonucleotides, treated or mock treated
the cells with IR, and then analyzed them by flow cytometry.
Downregulation of hnRNP K did not in itself cause significant
alterations to the cell-cycle distribution (Figure 5A; see also
Figure S2A); however, while cells treated with the control
siRNA (si-GFP) displayed a normal G1/S checkpoint arrest
following IR treatment, this response was almost completely
abolished in cells depleted for hnRNP K (Figure 5A and Fig-
ure S2A). In parallel studies, we analyzed the effects of de-
pleting hnRNP K from U2OS cells that are known to arrest
mainly in G2 in response to DNA damage. While U2OS cells
treated with the control GFP siRNA exhibited a clear G2/M
arrest following IR, this response was curtailed by hnRNP K
depletion or by siRNA depletion of p53 (Figure 5B and Figure
S2B). Taken together, these data reveal that hnRNP K is
required for the efficient induction of both the G1/S and
G2/M cell-cycle arrests in response to IR. Significantly,
when we analyzed IR-mediated cell-cycle responses in p53-
deficient SAOS2 cells, we found that the IR-induced G2/MCellarrest exhibited by these cells (probably mediated by Chk1
activation) took place whether or not hnRNP K was depleted
(Figure S2C). These data therefore reveal that hnRNP K has
selective effects on cell-cycle-checkpoint responses that are
mediated by p53.
hnRNP K Is Required for p53-Dependent
Transcription in Response to DNA Damage
Given the involvement of hnRNP K in cell-cycle-checkpoint
events that require p53 and because of previous work linking
hnRNP K to transcriptional control, we speculated that
hnRNP K might facilitate the induction of p53 target genes
following DNA damage. Indeed, while the p53 target pro-
teins p21, GADD45, HDM2, and p53R2 were strongly in-
duced by IR in p53-positive human U2OS cells that had
been treated with a control siRNA (si-GFP), little or no induc-
tion was observed in hnRNP K-depleted cells (Figure 6A).
Importantly, however, hnRNP K depletion did not affect IR-
induced p53 stabilization or phosphorylation of p53 on
Ser15 (Figure 6A), an event mediated primarily by ATM and
ATR (Canman et al., 1998; Khanna et al., 1998).
To explore the mechanism behind the above observa-
tions, we carried out RT-PCR analyses on samples derived
from cells that had been treated with control or hnRNP K
siRNAs and then exposed to IR. We found that hnRNP K de-
pletion prevented IR induction of the mRNAs for p21, HDM2,
and 14-3-3s, suggesting that hnRNP K exerts its effects at
the transcriptional level (Figure 6B). Indeed, when we used
a U2OS cell line containing a stably integrated luciferase
construct under the control of the synthetic p53-responsive
PG13 promoter (Kern et al., 1992), luciferase expression was
strongly induced by IR when these cells had been treated
with a control siRNA, but almost no induction was apparent
following hnRNP K depletion (Figure 6C). Similar effects of
hnRNP K knockdown were seen in U2OS cells transiently
transfected with a plasmid containing the gene coding for lu-
ciferase under the control of the p53-responsive p21 pro-
moter and also for p53-dependent transcription following
UV treatment (Figures 6D and 6E). By contrast, downregula-
tion of hnRNP K did not significantly affect luciferase ex-
pression directed by p53-independent promoters; these
included the constitutive SV40 early promoter, the serum-
inducible c-fos promoter, and a synthetic promoter driven
by the glucocorticoid-responsive elements (GREs; Figure
6D and Figure S3). Taken together, these data reveal that
hnRNP K specifically influences DNA-damage-induced ex-
pression of p53 target genes at the transcriptional level. Fur-
thermore, since hnRNP K is not required for IR-induced p53
phosphorylation or stabilization (Figure 6A), these results im-
ply that hnRNP K does not regulate p53 activation per se
but instead is required for p53 to promote the transcription
of its target genes. Moreover, as shown in Figure 6F, we
found that, when p53 is induced in the absence of DNA
damage—by treating cells with Nutlin or by forced p53 over-
expression—ensuing p53-dependent transcription is still
impaired upon hnRNP K depletion, albeit to a lesser degree
than in cells treated with IR. While these are clearly artificial
situations, they nevertheless reveal that the constitutive level
of hnRNP K present in cells not containing deliberately123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc. 1071
Figure 5. hnRNP K Is Required for Efficient G1 and G2 Cell-Cycle Arrest following DNA Damage
(A) MRC5 cells immortalized by ectopic expression of telomerase (tel-MRC5) were transfected with GFP siRNA or hnRNP K siRNA, mocked treated () or
treated with 20 Gy IR (+) 48 hr later, and then analyzed by flow cytometry 24 hr later. The amount of cells accumulating in G1 or S + G2 in irradiated cells is
given as a fold change relative to unirradiated cells.
(B) U2OS cells were analyzed in a similar fashion to those in (A) but, in addition to si-GFP and si-hnRNP K, siRNA for p53 (si-p53) was used to evaluate G2
arrest in response to IR. Levels of hnRNP K knockdown in tel-MRC5 (A) or U2OS (B) cells are also shown. In both (A) and (B), the plots represent the mean of
three independent experiments and error bars represent SEM.introduced DNA damage is intrinsically competent to pro-
mote p53-dependent transcription.
hnRNP K Interacts with p53, and Both Proteins
Localize to p53-Responsive Promoters in an
Interdependent Manner
Given the dependence of p53 transcriptional activity on
hnRNP K, we investigated the potential interaction between
the proteins by immunoprecipitation. Thus, we found that
p53 could be coimmunoprecipitated with hnRNP K from ex-
tracts derived from unirradiated or irradiated cells (Figure 7A).
Previous work has established that hnRNP K can serve as
a transcriptional activator following its recruitment to the pro-1072 Cell 123, 1065–1078, December 16, 2005 ª2005 Elsevier Incmoter regions of target genes (Ostrowski et al., 2003; Thakur
et al., 2003). We therefore used antibodies against endoge-
nous hnRNP K in chromatin immunoprecipitation (ChIP) ex-
periments to test for the potential recruitment of hnRNP K to
genes regulated by p53. As illustrated in Figure 7B, while
hnRNP K was weakly associated with the p21 and HDM2
promoters in the absence of exogenous DNA-damaging
agents, this association was rapidly and markedly enhanced
upon IR exposure but then returned to near basal levels after
3 hr. By contrast, IR did not trigger detectable recruitment of
hnRNP K to the GAPDH promoter that is not regulated in re-
sponse to DNA damage (Figure S4A). Notably, in contrast
with the data obtained with p53-positive U2OS cells, IR did.
not bring about the recruitment of hnRNP K to the p21 and
HDM2 promoters in p53-deficient SAOS2 cells (Figure 7B),
despite the fact that IR still triggered hnRNP K stabilization
in these cells (see Figure S4B). These results indicate that
the increased binding of hnRNP K to the p21 andHDM2 pro-
moters following IR treatment in U2OS cells does not simply
reflect higher levels of the protein and furthermore reveal that
hnRNP K recruitment to p53-responsive promoters requires
functional p53.
In parallel with the above analysis of hnRNP K recruitment,
we observed the expected recruitment of p53 to its target
genes in response to IR (Figure 7B). Strikingly, when we an-
alyzed cells that had been treated with a control siRNA or
had been siRNA depleted of hnRNP K, we found that the
IR-induced recruitment of p53 to the p21 andHDM2promot-
ers was severely compromised in the absence of hnRNP K
(Figure 7B), despite the fact that hnRNP K depletion does
not affect p53 stabilization following DNA damage in these
cells (Figure 6A). These findings thereby establish that p53
and hnRNP K depend on one another for their effective re-
cruitment to p53 target genes in response to DNA damage.
Consistent with this mutual dependency, while the kinetics
of p53 and hnRNPK stabilization in response to IR are some-
what different, their temporal profiles of recruitment and re-
tention on p53-dependent promoters were very similar
(see Figure S4C).
DISCUSSION
We have identified hnRNP K as a new component of the
mammalian DDR and have established that this protein is
crucial for cells to mount effective responses to genotoxic
agents. Specifically, following its ATM-dependent induction
after IR or its ATR-dependent induction after UV irradiation,
hnRNP K cooperates with p53 to elicit the activation of
p53 target genes and thereby trigger cell-cycle-checkpoint
events. A notable feature of hnRNP K induction by DNA
damage is its rapidity: it can be detected within 5min, and full
induction is reached within 30 min to 1 hr. As in many other
instances where protein levels are rapidly modulated, this re-
flects posttranscriptional control of (hnRNP K) protein stabil-
ity. Indeed, we have shown that hnRNP K is a direct target of
the ubiquitin E3 ligase HDM2/MDM2, a protein previously
connected with the DDR through its control of p53 activity
and levels (Iwakuma and Lozano, 2003). Furthermore—and
with striking parallels to the control of p53 in response to
DNA damage—we have shown that hnRNP K is targeted
for HDM2/MDM2-dependent proteasomal turnover in un-
damaged cells and that this degradation promptly ceases
upon the creation of DNA damage. Additionally, and with fur-
ther resonance with p53, hnRNP K forms a complex with
HDM2 in undamaged cells, and this complex is rapidly dis-
solved following DNA damage.
Although hnRNP K is a component of the hnRNP com-
plex, composed of mRNA binding proteins that facilitate var-
ious stages of mRNA biogenesis and maturation (Bomsztyk
et al., 2004; Dreyfuss et al., 1993), biochemical studies have
indicated that a significant proportion of it is not part of
the hnRNP complex and presumably has other functionsCell(Bomsztyk et al., 1997). Indeed, hnRNP K has been linked
with DNA-dependent processes including chromatin re-
modeling and gene transcription (Bomsztyk et al., 2004),
properties that are likely to reflect its ability to bind to DNA,
particularly ssDNA (Tomonaga and Levens, 1995; 1996). Be-
cause of its diverse functions, it is possible that hnRNP K
influences various aspects of the DDR. However, we have
found that its depletion does not prevent PIKK-dependent
phosphorylation of p53 on Ser15 or the focal recruitment
of DDR factors to sites of DNA damage, and, furthermore,
hnRNP K does not itself detectably accumulate at such sites
(A.M., unpublished data). Instead, our data indicate that the
main role of hnRNP K in the DDR is as a transcription co-
factor. Thus, it is specifically required for the induction of
p53 target genes, acting at the level of transcription and
not through downstream events such as mRNA stability.
Furthermore, we have shown that hnRNP K is recruited to
the promoters of p53 target genes in a p53-dependent
manner, and it is required for p53 to be recruited to these
promoters as measured by ChIP analysis. These findings
thereby establish hnRNP K as a novel transcriptional co-
activator for p53.
A key outcome of hnRNP K and p53 cooperation is the in-
duction of the G1/S and G2/M cell-cycle checkpoints. Thus,
while normal telomerized MRC5 cells arrested in G1 in re-
sponse to IR, this did not take place following hnRNP K de-
pletion. This presumably reflects an inability of hnRNP K-
depleted cells to induce p21, which normally mediates G1
arrest by inhibiting cyclin-dependent kinases (Harris and
Levine, 2005) and by preventing PCNA from participating
in DNA replication with DNA polymerase d (Waga et al.,
1994). Notably, p53 is also required for efficient G2/M arrest
in response to DNA damage in certain cell lines (Taylor and
Stark, 2001); here, DNA damage is thought to trigger the
p53-dependent induction of p21, GADD45, and 14-3-3s,
which are required for effective suppression of the G2/M
transition (Taylor and Stark, 2001). Consistent with the fact
that hnRNP K depletion abrogates induction of these pro-
teins, we have found that depletion of hnRNP K (or p53)
from U2OS cells prevented them from efficiently arresting
in G2/M in response to DNA damage. We obtained similar
results with other p53-positive cells, such as HCT116, that
also normally arrest in G2/M following DNA damage (A.M.,
unpublished data). These effects of hnRNP K were p53 de-
pendent, as its depletion did not abrogate DNA-damage-
induced cell-cycle arrest in p53-deficient SAOS2 cells.
How is it that p53 and hnRNP K cooperate at the
transcriptional level? Based on our data, we surmise that
hnRNP K facilitates the assembly and/or stability of p53 pro-
moter complexes. Significantly, hnRNP K and p53 can be
coimmunoprecipitated from extracts of cells that have, or
have not, been subject to DNA-damaging treatment, sug-
gesting that they interact both prior and subsequent to their
assembly onto transcriptional promoters. Previous work has
established that the DNA binding activity of p53 is central to
its biological functions as a tumor suppressor (Prives and
Hall, 1999), and several studies have shown that p53
binding—even to its cognate sequences—is not a stable
event and that p53 can dissociate from DNA in the absence123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc. 1073
Figure 6. hnRNP K Is Required for p53-Dependent Transcription
(A) Induction of p53-dependent transcription targets was assessed in U2OS cells treated with a control siRNA (si-GFP) or hnRNP K siRNA (si–hnRNP K),
and, 48 hr after siRNA transfection, cells were mock treated () or treated with 20 Gy IR (+); the induction of p53-dependent targets was determined by
Western blot analysis 12 hr later. hnRNP K levels (K) are shown, confirming siRNA knockdown, and p53 stabilization and phosphorylation on Ser15 were
determined 4 hr after IR treatment.
(B) Forty-eight hours following siRNA transfection, U2OS cells were mock treated or treated with 20 Gy IR and incubated for 6 hr before mRNA extraction.
RT-PCRs were performed with primers recognizing sequences within the mRNAs for p21, HDM2, and 14-3-3s. As a control, RT-PCR was carried out with
primers specific for GAPDH.
(C) U2OS cells stably transfected with a luciferase reporter gene under the control of multiple p53 binding sites (PG13-luc) were subjected to si-GFP or si-
hnRNP K treatment, and, 48 hr later, they were mock treated or exposed to IR (15 Gy). Luciferase activity was measured at the indicated times.1074 Cell 123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc.
Figure 7. hnRNP K Interacts with p53, and the Two Proteins Associate with p53-Dependent Promoters in an Interdependent
Manner
(A) Coimmunoprecipitation (IP) of hnRNP K with p53 was shown by using either hnRNP K antibody (IP/a-K) or p53 antibody (IP/a-p53) before or after
IR treatment (15 Gy) at the times indicated. Western blot analysis was with hnRNP K antibody (WB/a-K) or p53 antibody (WB/a-p53). UIg is an unrelated
antibody used as a control.
(B) U2OS (p53-positive) and SAOS2 (p53-negative) cells that had been mock treated or treated with IR (20 Gy) and incubated for the indicated times were
subjected to ChIP with either hnRNP K antibody (ChIP-K) or p53 antibody (ChIP-p53). Precipitated DNA was subjected to PCR with primers covering the
p53-response elements of the p21 or HDM2 promoters. ChIPs with anti-p53 antibody were carried out on lysates from U2OS cells obtained 48 hr after
transfection with GFP siRNA or hnRNP K siRNA.of other factors (Banerjee et al., 2004; Prives and Hall, 1999).
If hnRNP K stabilizes p53 promoter binding, it could help cir-
cumvent this instability. hnRNP K might also help p53 to
search for its target sites in the genome, an event that Prives
and colleagues have implicated as a key rate-limiting step in
the activation of p53 target genes (McKinney et al., 2004).
The recent identification of the DEAD box RNA helicase
p68 as a new p53 coactivator further fuels this type of model
(Bates et al., 2005). Notably, hnRNP K has been reported to
display some sequence preference for its binding to ssDNA,
so it is possible that it differentially affects various p53 target
promoters, depending on their sequence features and pro-
pensity to form ssDNA. Whatever the case, it will be of inter-Cellest to see whether hnRNP K regulates transcription from all,
or only a subset of, p53 target genes. It will also be interesting
to determine whether the influence of hnRNP K extends to
genes induced by DNA damage via p53-independent mech-
anisms (Elkon et al., 2005).
In addition to interacting with one another, it seems likely
that hnRNP K and p53 will also interact with other transcrip-
tion proteins, thus further stabilizing the promoter/p53/
hnRNP K complex and facilitating additional steps of tran-
scription-complex assembly together with transcriptional ini-
tiation itself. Significantly, several factors that interact with
p53 and stimulate its DNA binding ability have also been re-
ported to bind hnRNP K; these include high-mobility group 1(D) U2OS cells transiently transfected with luciferase reporter vector under the control of a p53-dependent promoter (p21-luc) or p53-independent promoter
(SV40-luc) were analyzed for their luciferase activity as above. Luciferase activity is given as a percentage relative to activity found in unirradiated SV40-luc-
transfected cells treated with si-GFP.
(E) U2OS cells stably transfected with PG13-luc were subjected to UV (25 J/m2) and incubated for the times indicated before determining luciferase activity.
(F) U2OS (PG13-luc) cells were subjected to si-GFP or si-hnRNP K and mock treated or treated with IR (20 Gy) or the MDM2 antagonist Nutlin (10 mm) for
24 hr or were transiently transfected with a p53 overexpression vector (OE). Luciferase activity was thenmeasured. In (C)–(F), the plots represent themean of
at least three independent experiments ± SEM.123, 1065–1078, December 16, 2005 ª2005 Elsevier Inc. 1075
protein (HMBG1; Dintilhac and Bernues, 2002; Jayaraman
et al., 1998), the Y box binding protein (YB-1; Okamoto
et al., 2000; Shnyreva et al., 2000), and the TATA-box bind-
ing protein (TBP; Farmer et al., 1996; Michelotti et al., 1996).
It is thus tempting to speculate that the linking of hnRNP K
and p53 within a cooperative multiprotein complex would
yield a higher degree of stability, promoter discrimination,
and regulatory control than could be achieved by a more
simple system involving fewer noncooperative components.
It is noteworthy that hnRNP K is modified in response to var-
ious stimuli (Mandal et al., 2001; Ostrowski et al., 2001) and
has been reported to interact with a range of other proteins
(Bomsztyk et al., 1997). Perhaps these control hnRNP K ac-
tivity in ways that allows DNA-damage-induced transcrip-
tional events to be fine tuned by other signals.
Mutations in DDR components are strongly linked with
cancer, and ongoing genome instability appears to be a hall-
mark of cancerous cells (Kastan and Bartek, 2004). It will
hence be of interest to see whether hnRNP K mutations
are associated with certain cancers. Given its widespread
functions, however, we speculate that total loss of hnRNP K
will be lethal to a cell, so if cancer-causing hnRNP K muta-
tions do occur, then these will probably be more subtle—
for instance, only affecting its DNA-damage-specific func-
tions. Finally, it is noteworthy that hnRNP K overexpression
has been linked to a range of cancers and has been associ-
ated with resistance to the DSB-inducing agent etoposide
(Pino et al., 2003; Urbani et al., 2005). Considering these fea-
tures together with its key role in p53-dependent transcrip-
tion, hnRNP Kmay represent an attractive target for antican-
cer therapies.
EXPERIMENTAL PROCEDURES
Cell Culture, Expression Vectors, Transfection,
and Flow Cytometry
Standard conditions and procedures were used for culturing mammalian
cells. Transfections were done with calcium phosphate, and cells were
harvested 48 hr afterwards. U2OS, SAOS2, HCT116, MRC5, and telo-
merized MRC5 cell lines were from Cancer Research UK. Mdm2/
p53/MEF cells were from G. Lozano (Anderson Cancer Center, Hous-
ton), AT cells were from Y. Shiloh (Tel Aviv University, Israel), HA-MDM2
constructs were obtained from H. Lu (Oregon Health and Science Univer-
sity, Portland, OR), and GST-HDM2 was from M. Oren (Weizmann Insti-
tute, Israel). For flow cytometry, cells were washed with PBS, trypsinized,
and fixed at 4ºC with 70% ethanol. Cells were then washed with PBS and
incubated in PBS containing 30 mg/ml of RNase and stained 30 min at
37ºC with propidium iodide in the dark. DNA content was analyzed by
flow cytometry.
Irradiation and Cell Extracts
Cells were treated with g irradiation or UV at 50%–70% confluency (in 10
ml of medium in a 10 cm Petri dish for IR and 5 ml for UV). After recovery,
cells were lysed in SDS sample buffer without bromophenol blue and
equal amounts of protein analyzed by Western blotting.
Antibodies, Western Immunoblotting, and Immunoprecipitation
The monoclonal antibody recognizing hnRNP K was from G. Dreyfuss
(University of Pennsylvania School of Medicine, Philadelphia). p53,
R2p53, Hdm2, pChk2 (T68), and anti-ubiquitin antibodies were from
Cell Signaling; HA antibody was fromCovance; b-tubulin and a-actin anti-
bodies were from Abcam; and p21, Gadd45a, and ATR antibodies were
from Santa Cruz Biotechnology. Cell extracts were resolved by 10%SDS-1076 Cell 123, 1065–1078, December 16, 2005 ª2005 Elsevier InPAGE, transferred onto nitrocellulose, and blotted by standard proce-
dures. For immunoprecipitation, cells were washed with PBS and lysed
on ice in RIPA buffer supplemented with protease inhibitors. Lysates
were sheared by pipetting repeatedly through a needle and cleared by
centrifugation. Extracts were precleared with 50 ml of Protein A Sepharose
(Sterilin) for 2 hr at 4ºC and incubated for 2 hr with antibody and then over-
night with 50 ml of Protein A Sepharose. Beads were washed with RIPA
buffer three times, and bound proteins were recovered by boiling in
SDS sample buffer.
In Vitro Ubiquitylation
Ubiquitylation was done as previously (Leng et al., 2003). Briefly, the re-
action was performed in 30 ml of 50 mM Tris-HCl (pH 7.4), 2 mM ATP,
5 mM MgCl2, 2 mM DTT, pure hnRNP K (500 ng), GST-HDM2 (or GST-
HDM2Dring) (500 ng), rabbit E1 (200 ng), ubcH5b as E2 (200 ng), and
ubiquitin (10 mg). After incubation at 30ºC for 1.5 hr, the reactions were
stopped with 2 SDS loading buffer, heated to 95ºC for 5 min, and ana-
lyzed by Western blotting.
siRNA Design and Transfection
RNA duplexes of 21 nucleotides targeting the human hnRNP K, HDM2,
p53, or ATR mRNAs were designed, chemically synthesized, and sup-
plied in the 20-deprotected and desalted form by Dharmacon (Lafayette,
CO). Oligonucleotide sequences are in Table S1 (see Supplemental Data).
In each case, the sequence was subjected to a BLAST search to ensure
that the siRNA was specific to the targeted gene. U2OS cells were grown
to 20%–50% confluency, and oligofectamin-mediated transient transfec-
tion of siRNA was done in 60 mm plates. siRNA (75 mM) and 7 ml of oli-
gofectamin were mixed and incubated for 20 min at room temperature
and added to each plate in DMEM containing 5% serum. After 24 hr,
the medium was changed to DMEM supplemented with 10% FBS, and
cells were left in culture for an additional 24 hr to bring about downregu-
lation. GFP siRNAs were used as a control.
RT-PCR and Luciferase Expression Analyses
Total RNA was isolated with TRIzol (Invitrogen) from U2OS cells trans-
fected with siRNA against hnRNP K or GFP and irradiated or left un-
treated. RT-PCR was done as described (Zeng et al., 2002). PCR prod-
ucts were analyzed on an agarose gel followed by ethidium-bromide
staining. Primers used for PCR of p21, HDM2, and GAPDH were de-
scribed previously (Zeng et al., 2002). For luciferase expression, U2OS
cells stably transfected with an artificial p53 binding site repeat (PG13;
13 copies of GGACGGACCTGACCGGACC; Kern et al., 1992) cloned up-
stream of the luciferase coding sequence in a pGL3 basic vector
(Promega) or transiently transfected by luciferase expression vectors un-
der either the p21 promoter or SV40 early promoter were mock treated or
treated with IR or UV and allowed to recover. Cells were then harvested,
and luciferase activity was measured according to the manufacturer’s
protocol (Promega).
Chromatin Immunoprecipitation
ChIP was done with U2OS or SAOS2 cells as described (Espinosa et al.,
2003). Primers used for PCR of p21, HDM2, andGAPDH were described
previously (McKinney et al., 2004; Zeng et al., 2002).
Supplemental Data
Supplemental Data include one table and four figures and can be found
with this article online at http://www.cell.com/cgi/content/full/123/6/
1065/DC1/.
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